Health Canada granted approval for Imbruvica (ibrutinib), as an oral, once-daily, single-agent therapy for the treatment of patients with Waldenström’s macroglobulinemia. This approval was based on an investigator-led, multicenter, prospective, single-arm study in 63 patients who had received at least one prior therapy. The results of the study were published in the New England Journal...
In this episode of In the Headlines, former NCI Director Kimryn Rathmell speaks with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, about the HHS layoffs and their potential impact on mental health. These layoffs—and the broader uncertainty introduced by the current administration’s actions—are a form of trauma, Rathmell says.
